CTLA4 and Miyoshi myopathy: A retrospective single institutional analysis of anti‐CTLA‐4, PD‐1, or PD‐L1 therapy in patients showed that patients with metastatic CM had median overall survival of 45 months, compared with 17 months for AM (p = 0.047), 18 months for MM (p = 0.003), and 12 months for UM (p < 0.001) (Klemen et al., 2020).